Analysts Set Emergent BioSolutions Inc. (NYSE:EBS) PT at $28.00

Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) has been given an average recommendation of “Hold” by the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $28.00.

EBS has been the topic of a number of recent research reports. StockNews.com initiated coverage on Emergent BioSolutions in a research report on Thursday, May 18th. They set a “sell” rating on the stock. JPMorgan Chase & Co. reaffirmed an “underweight” rating and set a $9.00 price objective (down previously from $23.00) on shares of Emergent BioSolutions in a research report on Friday, March 17th. TheStreet lowered Emergent BioSolutions from a “c-” rating to a “d” rating in a research report on Monday, February 27th. Finally, Benchmark raised Emergent BioSolutions from a “hold” rating to a “buy” rating and set a $22.00 price objective on the stock in a research report on Monday, April 10th.

Institutional Investors Weigh In On Emergent BioSolutions

Hedge funds have recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can acquired a new stake in Emergent BioSolutions in the third quarter valued at about $1,163,000. Everence Capital Management Inc. purchased a new position in Emergent BioSolutions in the fourth quarter valued at about $219,000. Federated Hermes Inc. increased its holdings in Emergent BioSolutions by 1,728.0% in the third quarter. Federated Hermes Inc. now owns 402,698 shares of the biopharmaceutical company’s stock valued at $8,453,000 after buying an additional 380,668 shares in the last quarter. AlphaCrest Capital Management LLC increased its holdings in Emergent BioSolutions by 210.4% in the third quarter. AlphaCrest Capital Management LLC now owns 33,648 shares of the biopharmaceutical company’s stock valued at $706,000 after buying an additional 22,807 shares in the last quarter. Finally, Duality Advisers LP increased its holdings in Emergent BioSolutions by 36.1% in the fourth quarter. Duality Advisers LP now owns 77,298 shares of the biopharmaceutical company’s stock valued at $913,000 after buying an additional 20,494 shares in the last quarter. Institutional investors and hedge funds own 80.44% of the company’s stock.

Emergent BioSolutions Stock Performance

NYSE EBS opened at $8.57 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.70 and a current ratio of 1.00. The stock’s fifty day moving average is $9.67 and its two-hundred day moving average is $11.74. The firm has a market capitalization of $432.34 million, a P/E ratio of -1.06 and a beta of 0.93. Emergent BioSolutions has a fifty-two week low of $7.74 and a fifty-two week high of $40.45.

Emergent BioSolutions (NYSE:EBS – Get Rating) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($3.17) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by ($1.50). Emergent BioSolutions had a negative return on equity of 20.18% and a negative net margin of 41.20%. The firm had revenue of $165.10 million for the quarter, compared to analyst estimates of $142.85 million. During the same quarter last year, the company earned $0.18 earnings per share. The firm’s revenue for the quarter was down 46.3% on a year-over-year basis. On average, research analysts anticipate that Emergent BioSolutions will post -1.29 earnings per share for the current year.

Emergent BioSolutions Company Profile

(Get Rating)

Emergent BioSolutions Inc engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm’s products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV.